February 2010 Volume 6 Number 2
Visit Nature Reviews Rheumatology online to browse the journal.
Now available at
http://links.ealert.nature.com/ctt?kn=20&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Please note that you need to be a subscriber to enjoy full text access
to Nature Reviews Rheumatology online. To purchase a subscription, please
visit: http://links.ealert.nature.com/ctt?kn=76&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Alternatively, to recommend a subscription to your library, please visit
http://links.ealert.nature.com/ctt?kn=52&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
*********************************************************************
Nature Reviews Rheumatology Impact Factor: 5.677*
(*Journal Citation Reports, Thomson, 2008)
*********************************************************************
=========================== ADVERTISEMENT ===========================
VideoCap 3.0 D1 is a video-bio-microscope to investigate non-invasively,
by capillaroscopic technique, microcirculatory morphological alterations
that characterize several rheumatic conditions: secondary Raynaud's
phenomenon, systemic sclerosis, dermatomyositis, Sjogren's syndrome,
systemic lupus erythematosus.
http://links.ealert.nature.com/ctt?kn=1&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
DS Medica Milan - Italy
http://links.ealert.nature.com/ctt?kn=2&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
=====================================================================
=========================== ADVERTISEMENT ===========================
European Congress of Radiology - ECR 2010: March 4-8, Vienna, Austria
Attention! New congress dates: Thursday to Monday
Topics of interest:
- Special Focus Session on Optimal Imaging of Muscle Pathology
- Mini Courses on Extremity Joint MRI: Lower Extremity and Upper Extremity
- Musculoskeletal Refresher Courses
- Hands-On Workshops on Musculoskeletal US: Hand and Wrist, Foot and Ankle
Find out more at
http://links.ealert.nature.com/ctt?kn=101&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Register online now at
http://links.ealert.nature.com/ctt?kn=47&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
=====================================================================
"Officially endorsed by the Asia Pacific League of Associations for
Rheumatology"
----------------------
RESEARCH HIGHLIGHTS
----------------------
Osteoarthritis: Blocking hedgehog signaling might have therapeutic
potential in OA
p61 | doi:10.1038/nrrheum.2009.270
http://links.ealert.nature.com/ctt?kn=27&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Chronic pain-a risk factor for falls
p62 | doi:10.1038/nrrheum.2009.272
http://links.ealert.nature.com/ctt?kn=25&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Rheumatoid arthritis: Time to give up on chemokine receptor antagonism
for RA therapy?
p62 | doi:10.1038/nrrheum.2009.273
http://links.ealert.nature.com/ctt?kn=23&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Connective tissue diseases: Another reason to target IL-6
p63 | doi:10.1038/nrrheum.2009.269
http://links.ealert.nature.com/ctt?kn=21&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
IN BRIEF
Rheumatoid arthritis | Osteoarthritis
p63 | doi:10.1038/nrrheum.2009.275
http://links.ealert.nature.com/ctt?kn=60&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Osteoarthritis: Targeting cartilage erosion in OA
p64 | doi:10.1038/nrrheum.2009.266
http://links.ealert.nature.com/ctt?kn=94&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Bone: Novel microRNA expressed in osteoblasts promotes bone formation
p64 | doi:10.1038/nrrheum.2009.268
http://links.ealert.nature.com/ctt?kn=92&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Chicken collagen for RA
p65 | doi:10.1038/nrrheum.2010.1
http://links.ealert.nature.com/ctt?kn=90&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Stem cells: Chondrogenesis induced from human embryonic stem cells
p66 | doi:10.1038/nrrheum.2009.265
http://links.ealert.nature.com/ctt?kn=88&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Rheumatoid arthritis: Monitoring serum concentration of infliximab might
improve RA disease control
p66 | doi:10.1038/nrrheum.2009.271
http://links.ealert.nature.com/ctt?kn=31&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
----------------------
NEWS AND VIEWS
----------------------
Immunology: TL1A in the inflammatory network in autoimmune diseases
Jagadeesh Bayry
p67 | doi:10.1038/nrrheum.2009.263
Several lines of evidence both from experimental models and from clinical
studies reveal that TNF-like ligand 1A (TL1A) and its interaction with
death receptor 3 (DR3) is critically involved in the pathogenesis of
rheumatoid arthritis and other autoimmune diseases.
http://links.ealert.nature.com/ctt?kn=33&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Rheumatoid arthritis: Can we achieve true drug-free remission in patients
with RA?
Yvonne P. M. Goekoop-Ruiterman and Tom W. J. Huizinga
p68 | doi:10.1038/nrrheum.2009.253
Since the introduction of new biologic agents and intensive treatment
strategies that aim to tightly control disease activity, clinical remission
has become a realistic target in patients with rheumatoid arthritis. Once
patients are in continuous remission, however, is it realistic to consider
withdrawing DMARD therapy?
http://links.ealert.nature.com/ctt?kn=43&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Ethics: Investigators' interests: what should trial participants be told?
Paul L. Romain
p70 | doi:10.1038/nrrheum.2009.264
Minimizing the potential adverse effects of clinical investigators'
financial conflicts of interest involves, in part, determining how much
of an investigator's 'business' should be disclosed to participants in
research studies. What should be disclosed and why? How will we know if
disclosure matters?
http://links.ealert.nature.com/ctt?kn=38&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Epidemiology: Interpreting studies of interactions between RA risk factors
Elizabeth W. Karlson and Karen H. Costenbader
p72 | doi:10.1038/nrrheum.2009.276
Interactions between HLA and PTPN22 genotypes and smoking have been
implicated in overall susceptibility to rheumatoid arthritis as well as
the incidence of particular disease phenotypes in case-control and
case-only studies. As recent epidemiological evidence shows, deciphering
these interactions demands consideration of the analytical approach used.
http://links.ealert.nature.com/ctt?kn=40&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Bone diseases: Interferon regulatory factor-8 suppresses osteoclastogenesis
Hermann Wagner
p73 | doi:10.1038/nrrheum.2009.274
To date, understanding of the molecular mechanisms of bone metabolism
has centered on three tumor necrosis factor family members-RANK, its
ligand RANKL and its decoy receptor osteoprotegrin. This view should
now be modified, however, to incorporate the role of interferon
regulatory factor-8.
http://links.ealert.nature.com/ctt?kn=42&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
----------------------
REVIEWS
----------------------
Disease modification in ankylosing spondylitis
Walter P. Maksymowych
p75 | doi:10.1038/nrrheum.2009.258
Any form of treatment for patients with ankylosing spondylitis (AS) is
defined as being disease-modifying on the basis of its ability to decrease
inflammation, improve function and inhibit the progression of structural
damage. This Review outlines clinical outcomes that are relevant to the
concept of disease modification, looks at what is known about the
disease-modifying properties of currently available agents and considers
the challenges involved in developing future therapies for AS.
Abstract: http://links.ealert.nature.com/ctt?kn=49&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=4&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Management of glucocorticoid-induced osteoporosis
Juliet Compston
p82 | doi:10.1038/nrrheum.2009.259
The clinical importance of glucocorticoid-induced osteoporosis has gained
increasing recognition over recent years, but its management generally
remains suboptimal. The currently recommended pharmacologic therapies and
the development of clinical guidelines for the management of patients with
this condition are discussed in this article.
Abstract: http://links.ealert.nature.com/ctt?kn=48&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=8&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Invariant natural killer T cells in rheumatic disease: a joint dilemma
Michael B. Drennan, Sandrine Aspeslagh and Dirk Elewaut
p90 | doi:10.1038/nrrheum.2009.261
Invariant natural killer T cells have been implicated in a number of
autoimmune diseases. In this Review, the authors highlight recent
advances in our understanding of distinct subsets of these cells and
the immunoregulatory cytokines they produce, and discuss whether inducing
differential cytokine responses in these cells could be exploited to
develop cell-based therapies.
Abstract: http://links.ealert.nature.com/ctt?kn=46&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=18&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Osteoporosis: impact on health and economics
Nicholas Harvey, Elaine Dennison and Cyrus Cooper
p99 | doi:10.1038/nrrheum.2009.260
Osteoporosis is a highly prevalent disease that leads to bone fragility
and subsequent fracture, most commonly at the hip, spine and wrist. This
article reviews the epidemiology of this potentially devastating disease,
highlighting the incidence and prevalence of osteoporotic fractures, the
resulting morbidity and mortality and the associated costs both to the
individual and to society as a whole.
Abstract: http://links.ealert.nature.com/ctt?kn=45&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=54&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
The contribution of Asian researchers to the field of rheumatology
Yoshihisa Yamano and Kusuki Nishioka
p106 | doi:10.1038/nrrheum.2009.257
Asian researchers have been at the forefront of many topics in the field
of Rheumatology, from the identification of disease entities that were
first observed in the region to the establishment of the field of
osteoimmunology. In this Review, Yamano and Nishioka highlight the ongoing
contribution of Asian researchers to our understanding and treatment of
rheumatic diseases.
Abstract: http://links.ealert.nature.com/ctt?kn=44&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=61&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
----------------------
PERSPECTIVES
----------------------
OPINION
Autoantibodies as predictive tools in systemic sclerosis
Svetlana I. Nihtyanova and Christopher P. Denton
p112 | doi:10.1038/nrrheum.2009.238
Autoantibodies-predominantly antinuclear antibodies-are strong predictors
of disease outcome and the pattern of organ complications in patients with
systemic sclerosis (SSc). In conjunction with improved methods to detect
and evaluate autoantibodies, this strong association offers a real chance
for risk stratification and disease assessment in patients with SSc.
Abstract: http://links.ealert.nature.com/ctt?kn=50&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Article: http://links.ealert.nature.com/ctt?kn=64&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
=========================== ADVERTISEMENT ===========================
Nature Reviews Immunology
Poster on Regulatory T cells
Regulatory T cells are vital for keeping the immune system in check, and
they have been the focus of extensive research over the past few years.
This Poster provides an updated overview of the development, phenotype
and functions of regulatory T cells, in particular those subsets that
express the transcription factor forkhead box P3 (FOXP3).
Download the Poster for FREE at:
http://links.ealert.nature.com/ctt?kn=84&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
Produced with support from
StemCell Technologies
http://links.ealert.nature.com/ctt?kn=85&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
=====================================================================
You have been sent this Table of Contents Alert because you have opted
in to receive it. You can change or discontinue your e-mail alerts at
any time, by modifying your preferences on your nature.com account at:
http://links.ealert.nature.com/ctt?kn=51&m=34601061&r=MTc2NDQ4MTc5OAS2&b=2&j=NjY3OTQ5ODIS1&mt=1&rt=0
(You will need to log in to be recognised as a nature.com registrant).
For further technical assistance, please contact our registration department:
registration@nature.com
For print subscription enquiries, please contact our subscription department:
subscriptions@nature.com
For other enquiries, please contact our customer feedback department:
feedback@nature.com
Nature Publishing Group | 75 Varick Street, 9th Floor | New York |
NY 10013-1917 | USA
Nature Publishing Group's worldwide offices:
London - Paris - Munich - New Delhi - Tokyo - Melbourne -
San Diego - San Francisco - Washington - New York - Boston
(c) Copyright 2010 Nature Publishing Group
=====================================================================
